Evidence map›Paper›PMID 39207229›Full record

ReviewCA: a cancer journal for clinicians

Geriatric assessment for the practicing clinician: The why, what, and how.

Allison Magnuson, Kah Poh Loh, Fiona Stauffer, William Dale, Nikesha Gilmore, Sindhuja Kadambi, Heidi D Klepin, Kaitlin Kyi, Lisa M Lowenstein, Tanyanika Phillips and 6 more

Abstract readReview
In one paragraph

Review in CA: a cancer journal for clinicians. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. How to distinguish pancreatic tumors and assess the necessity for biopsy.World journal of gastrointestinal endoscopy · 2025
    Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Data, Models, and Visuals: How Data Science Methods Can Augment (Geriatric) Oncology Research.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025
    Article
  12. Review
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Allison MagnusonDivision of Hematology/Oncology, Department of Medicine, University of Rochester Medical Center, Rochester, New York, USA.
Kah Poh LohDivision of Hematology/Oncology, Department of Medicine, University of Rochester Medical Center, Rochester, New York, USA.ORCID 0000-0002-6978-0418
Fiona StaufferDivision of Hematology/Oncology, Department of Medicine, University of Rochester Medical Center, Rochester, New York, USA.
William DaleDepartment of Supportive Care, City of Hope, Antelope Valley, Duarte, California, USA.ORCID 0000-0001-8674-9394
Nikesha GilmoreDivision of Supportive Care in Cancer, Department of Surgery, University of Rochester Medical Center, Rochester, New York, USA.ORCID 0000-0002-5079-1723
Sindhuja KadambiDivision of Hematology/Oncology, Department of Medicine, University of Rochester Medical Center, Rochester, New York, USA.ORCID 0000-0003-0875-1864
Heidi D KlepinSection on Hematology and Oncology, Department of Medicine, Wake Forest School of Medicine, Wake Forest, North Carolina, USA.ORCID 0000-0002-6262-1123
Kaitlin KyiDivision of Hematology/Oncology, Department of Medicine, University of Rochester Medical Center, Rochester, New York, USA.
Lisa M LowensteinDepartment of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0003-3481-5980
Tanyanika PhillipsDepartment of Medical Oncology and Therapeutics, City of Hope, Antelope Valley, Duarte, California, USA.
Erika RamsdaleDivision of Hematology/Oncology, Department of Medicine, University of Rochester Medical Center, Rochester, New York, USA.ORCID 0000-0002-2246-168X
Melody K SchiaffinoDepartment of Radiation Medicine and Applied Sciences, University of California San Diego School of Medicine, La Jolla, California, USA.ORCID 0000-0002-5917-7383
John F SimmonsCancer and Aging Research Group SCOREboard, City of Hope, Duarte, California, USA.
Grant R WilliamsDivision of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.ORCID 0000-0003-4294-5232
Jason ZittelDivision of Hematology/Oncology, Department of Medicine, University of Rochester Medical Center, Rochester, New York, USA.
Supriya MohileDivision of Hematology/Oncology, Department of Medicine, University of Rochester Medical Center, Rochester, New York, USA.ORCID 0000-0003-0867-327X

Funding

URCC NCORP Research BaseUG1CA189961 · NCI · UNIVERSITY OF ROCHESTER · PI Michelle C Janelsins, KAREN M. MUSTIAN · 2014 to 2026
$67.7M
Geriatric Oncology Research Infrastructure to Improve Clinical CareR33AG059206 · NIA · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI WILLIAM DALE, Heidi Diana Klepin · 2020 to 2026
$5.1M
Enhancing Triadic Communication About Cognition for Older Adults with Alzheimer's Disease or Related Dementias Facing a Cancer Management DecisionR01AG077053 · NIA · UNIVERSITY OF ROCHESTER · PI Allison Marian Magnuson · 2022 to 2026
$2.5M
A Patient-Oriented Research Program in Geriatric OncologyK24AG056589 · NIA · UNIVERSITY OF ROCHESTER · PI Supriya G. Mohile · 2018 to 2026
$1.5M
Mentoring the Next Generation of Geriatric Oncology Researchers in Patient-Oriented Research to Improve the Care of Older Adults with CancerK24AG055693 · NIA · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI WILLIAM DALE · 2018 to 2026
$1.4M
Mitigating Cancer-Related Cognitive Dysfunction in Older Adults with Breast CancerK76AG064394 · NIA · UNIVERSITY OF ROCHESTER · PI MAGNUSON, ALLISON MARIAN · 2019 to 2023
$1.3M
A novel mobile health exercise intervention for older patients with myeloid neoplasmsR00CA237744 · NCI · UNIVERSITY OF ROCHESTER · PI LOH, KAH POH · 2021 to 2023
$747k
A Phase II Randomized Placebo Controlled Trial of Epigallocatechin-3-Gallate (EGCG) on Physical Frailty and Tumor Necrosis Factor-alpha and Associated Immune Markers in Older Cancer SurvivorsK01CA276257 · NCI · UNIVERSITY OF ROCHESTER · PI Nikesha Gilmore · 2023 to 2026
$674k
Improving age-related risk assessment and documentation for diverse older adults with cancerK01AG068592 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Melody K Schiaffino · 2022 to 2026
$673k
Epigenetic markers, functional status, and exercise in older adults with myeloid neoplasmsR03AG073985 · NIA · UNIVERSITY OF ROCHESTER · PI LOH, KAH POH · 2022 to 2023
$308k
American Cancer Society MRSG-18-225-01-CPPBBristol Myers Squibb FoundationConquer Cancer Foundation American Society of Clinical Oncology-Walther Cancer Foundation Career Development AwardNCI NIH HHS K01 CA276257NCI NIH HHS K01CA276257NCI NIH HHS R00 CA237744NCI NIH HHS R00CA237744NCI NIH HHS UG1 CA189961NIA NIH HHS K01 AG068592NIA NIH HHS K01AG068592NIA NIH HHS K24 AG055693NIA NIH HHS K24 AG056589NIA NIH HHS K24AG056589NIA NIH HHS K76 AG064394NIA NIH HHS R01 AG077053NIA NIH HHS R03 AG073985NIA NIH HHS R03AG073985NIA NIH HHS R0I AG077053NIA NIH HHS R33 AG059206NIMHD NIH HHS L32 MD013114Patient-Centered Outcomes Research Institute DI-2020C3-21003
6 · The paper itself

Abstract

Older adults with cancer heterogeneously experience health care, treatment, and symptoms. Geriatric assessment (GA) offers a comprehensive evaluation of an older individual's health status and can predict cancer-related outcomes in individuals with solid tumors and those with hematologic malignancies. In the last decade, randomized controlled trials have demonstrated the benefits of GA and GA management (GAM), which uses GA information to provide tailored intervention strategies to address GA impairments (e.g., implementing physical therapy for impaired physical function). Multiple phase 3 clinical trials in older adults with solid tumors and hematologic malignancies have demonstrated that GAM improves treatment completion, quality of life, communication, and advance care planning while reducing treatment-related toxicity, falls, and polypharmacy. Nonetheless, implementation and uptake of GAM remain challenging. Various strategies have been proposed, including the use of GA screening tools, to identify patients most likely to benefit from GAM, the systematic engagement of the oncology workforce in the delivery of GAM, and the integration of technologies like telemedicine and mobile health to enhance the availability of GA and GAM interventions. Health inequities in minoritized groups persist, and systematic GA implementation has the potential to capture social determinants of health that are relevant to equitable care. Caregivers play an important role in cancer care and experience burden themselves. GA can guide dyadic supportive care interventions, ultimately helping both patients and caregivers achieve optimal health.

Indexed as

Geriatric AssessmentNeoplasmsQuality of LifeAdvance Care PlanningAgedCaregiversHumansMedical OncologyTelemedicineaginggeriatric assessmentgeriatric oncologytreatment‐related toxicity

Identifiers

PMID39207229
PMCPMC11848937

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.